Abnormal blood cell production in myelofibrosis

Myelofibrosis is a rare bone marrow cancer that belongs to a group of blood cancers called Myeloproliferative neoplasms (MPNs).

Myelofibrosis is a rare bone marrow cancer that belongs to a group of blood cancers called Myeloproliferative neoplasms (MPNs). These cancers all start with the overproduction of blood cells within the bone marrow. Any type of blood cell can have production affected, including white blood cells, red blood cells, and platelets. Most of the cancers in this group, including Myelofibrosis, are slow growing, or indolent.

For most patients, they will be treated for their symptoms, which commonly include anemia, enlarged spleen, and easily bruising or bleeding. However, clinical trials provide alternative treatment options that are both curative an relieve symptoms caused by Myelofibrosis. Enrolling in a clinical trial can be an overwhelming process due to the large number available. To find personalized options, use a clinical trial tool like the SYNERGY AI: Clinical Trial Matching System, which uses an Artificial Intelligence engine to identify the best option for your case.


Hibya Haber Ajansı